Comparison of Nonablative Fractional Erbium Laser 1,340 nm and Microneedling for the Treatment of Atrophic Acne Scars: A Randomized Clinical Trial : Dermatologic Surgery

Secondary Logo

Journal Logo

Original Article

Comparison of Nonablative Fractional Erbium Laser 1,340 nm and Microneedling for the Treatment of Atrophic Acne Scars

A Randomized Clinical Trial

Cachafeiro, Thaís MD, ScM; Escobar, Gabriela MD, ScM; Maldonado, Gabriela MD, ScM; Cestari, Tania MD, PhD; Corleta, Oly MD, PhD

Author Information
Dermatologic Surgery 42(2):p 232-241, February 2016. | DOI: 10.1097/DSS.0000000000000597

Abstract

BACKGROUND 

The efficacy and safety of nonablative fractional laser for acne scars treatment has been described in several studies. Recently, microneedling treatment has been showing promising results with lower costs, quick healing time, and low risk of postinflammatory hyperpigmentation (PIH).

OBJECTIVE 

To compare the effectiveness and safety of nonablative fractional erbium laser 1,340 nm and microneedling for the treatment of facial atrophic acne scars.

METHODS 

Forty-six patients with atrophic facial acne scars were randomized to microneedling and laser groups, receiving 3 sessions performed monthly. Two blinded dermatologists applied the validated “Quantitative Global Grading System for Postacne Scarring” scale, before, 2 months, and 6 months after the treatment. Side effects were recorded at each follow-up visit and patient's satisfaction was evaluated.

RESULTS 

Both groups showed a significant improvement, and there was no statistically significant difference between results of both therapies (p = .264). The erythema after each session was longer in the laser group and 13.6% subjects experienced PIH. No PIH was observed in the microneedling group.

CONCLUSION 

This study shows that both nonablative fractional laser 1,340 nm and microneedling are comparable and effective in the treatment of atrophic acne scars. Microneedling is well tolerated, with fewer side effects and lower down time.

© 2016 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid